Ketamine Hydrochloride is a small molecule commercialized by Seelos Therapeutics, with a leading Phase II program in Major Depressive Disorder. According to Globaldata, it is involved in 6 clinical trials, of which 1 was completed, 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ketamine Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Ketamine Hydrochloride is expected to reach an annual total of $41 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ketamine Hydrochloride Overview

Ereska (intranasal ketamine, PMI-150, SLS-002) is under development for the treatment of suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). The drug candidate is administered through intranasal route. It acts by targeting glutamate ionotropic receptor AMPA type subunit (AMPA) and glutamate ionotropic receptor NMDA type subunit.

It was also under development for the treatment of postoperative pain and pain in cancer patients.

Seelos Therapeutics Overview

Seelos Therapeutics (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-008, SLS-007, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.
The operating loss of the company was US$70.9 million in FY2022, compared to an operating loss of US$63.9 million in FY2021. The net loss of the company was US$73.5 million in FY2022, compared to a net loss of US$66.1 million in FY2021.

For a complete picture of Ketamine Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.